Polycyclic aromatic hydrocarbons (PAH) are products of the incomplete combustion of organic materials, and they occur ubiquitously in the environment. They are also present in tobacco smoke. Some PAH have been classified as carcinogens; therefore, it is important to develop and assess suitable biomarkers for PAH exposure. A high-performance liquid chromatographic method with fluorescence detection was developed to determine 1-and 2-hydroxynaphthalene (1-and 2-OH-Nap), 2-hydroxyfluorene (2-OH-Flu), 2-/3-hydroxyphenanthrene (2-/3-OH-Phe), 1-/9-hydroxyphenanthrene (1-/9-OH-Phe), and 1-hydroxypyrene (1-OH-Pyr) in human urine. The method is sensitive (LOQ ranging from 0.01 ng/mL for 1-OH-Pyr to 1 ng/mL for the naphthols), precise (interday precision ranging from 1.4 to 6.9%), and accurate (97-106%). The method was applied to 108 urine samples from 25 nonsmokers and 83 smokers. 
Introduction
Polycyclic aromatic hydrocarbons (PAH) are formed during the incomplete combustion of organic materials, including tobacco (1) . There are a variety of important sources for the uptake of PAH in non-occupationally exposed persons, including tobacco smoke, diet, ambient air, and coal-tar-containing medications (2) . For nonsmokers, diet is estimated to contribute about 70% of the daily PAH burden (3) . Several studies have shown that the normal intake of dietary PAH, contributed mostly by cereals and vegetables, ranged from 3 to 17 µg/day (3) . Depending on the amount smoked, tobacco smoke could represent an additional PAH body burden, accounting for more than 80% in a heavy smoker (3) .
At least 11 PAH compounds have been shown to be carcinogenic (1) , and they may play a role in tobacco smoke carcinogenesis (4, 5) . Lung carcinogenesis in smokers has been associated with mutagenesis induced by benzo[a]pyrene (B[a]P) and related PAH (6) , although a number of studies have shown contrasting data (7, 8) . In mainstream cigarette smoke, over 500 PAH (including alkyl derivatives) have been either completely or partially identified (9) . Yields in mainstream cigarette smoke, using the FTC (U.S. Federal Trade Commission) or ISO (International Standard Organization) smoking regimes, have been reported in nanograms per cigarette for naphthalene (57-893), fluorene , phenanthrene , and pyrene (10-80) (10) (11) (12) (13) . Of these compounds, naphthalene has been classified as a Class 2B carcinogen ("possibly carcinogenic to humans") (14) . Most of the carcinogenic PAH in tobacco smoke have ≥ 4 condensed aromatic rings, such as B[a]P, and occur in the low nanogramsper-cigarette range (10, 15) , making them difficult to monitor with existing analytical techniques. However, the urinary monohydroxy metabolites of naphthalene, fluorene, phenanthrene, and pyrene are generally used as suitable surrogate biomarkers of PAH exposure (16, 17) .
PAH are metabolized by cytochrome P450 enzymes to yield, among other metabolites, phenolic monohydroxy compounds, which are conjugated to sulfates and glucuronides and excreted into the urine (18) .
Although the role of PAH in tobacco smoke carcinogenicity is not fully understood, the assessment of smoking-related exposure to PAH by suitable biomarkers is of toxicological importance. Urinary 1-hydroxypyrene (1-OH-Pyr) has often been used as a biomarker of exposure to PAH, including tobacco smoke exposure (19) (20) (21) . However, there are also data available for exposure to naphthalene (22) (23) (24) , fluorene (23, 25) , phenanthrene (23, 25, 26) , and B[a]P (27, 28) .
Numerous reported analytical techniques are capable of determining urinary PAH metabolite profiles, including highperformance liquid chromatography (HPLC) with fluorescence detection (HPLC-FD) (29, 30) , liquid chromatography with tandem mass spectrometry (LC-MS-MS) (17, 31) , gas chromatography with mass spectrometry (GC-MS) (32) (33) (34) , high-resolution mass spectrometry (GC-HRMS) (35) , and tandem mass spectrometry (GC-MS-MS) (36) .
There are advantages and disadvantages to using each method. For example, GC methods for phenolic PAH metabolites require derivatization of the analytes, but are characterized by their high separation power, which allows the differentiation of the isomeric monohydroxy PAH species. MS permits the application of isotope dilution techniques for quantification, which offers a greater degree of accuracy. HPLC-FD benefits from the high sensitivity of fluorescence detection to analytes with PAH moieties, and the availability of the instrumentation in many laboratories. Disadvantages include the lower level of separation compared to GC and the lower specificity relative to mass selective detection.
Multianalysis of PAH metabolites can be regarded as having an advantage over single metabolite analysis, particularly because ratios between PAH may vary with the source (10) . In humans, interindividual differences in PAH metabolism also occur (37) .
In view of this, an analytical method has been developed and validated for the simultaneous determination of urinary phenolic metabolites of naphthalene, fluorene, phenanthrene, and pyrene. The chemical structures of OH-PAH measured in this study are shown in Figure 1 . In order to develop biomarkers suitable for their future purpose, a number of criteria, underscored in the IOM report 'Clearing the Smoke' (38), were considered. These include an assessment of their specificity, sensitivity, and reproducibility, and qualification of a doseresponse relationship which is understood on a mechanistic basis. The method was applied to 108 urine samples derived from 25 nonsmokers and 83 smokers. For smokers, the influence of ISO tar yields of the cigarettes smoked was also investigated.
Experimental Chemicals
1-OH-Naphthalene (1-OH-Nap) and 2-OH-fluorene (2-OHFlu) were purchased from Sigma-Aldrich (Deisenhofen, Germany), and 2-OH-naphthalene (2-OH-Nap) was obtained from Fluka (Deisenhofen, Germany). 1-Hydroxypyrene (1-OHPyr) was purchased from Acros Organics (Geel, Belgium). 1-, 2-, 3-, 4-, and 9-OH-Phenanthrene (1-, 2-, 3-, 4,-and 9-OHPhe) were generously supplied by PD Dr. A. Seidel (Grosshansdorf, Germany).
HPLC-grade methanol and all other analytical grade organic solvents were from LGC Standards (Wesel, Germany). Water was obtained from a Seraldest purification system (Seraldest, Munich, Germany). Other chemicals and reagents used were at least of analytical grade. β-Glucuronidase/arylsulfatase (enzyme preparation from Helix pomatia, 4.5 and 14 U/mL) was purchased from Roche (Mannheim, Germany).
Urine samples
One hundred and eight 24-h urine samples stored at -25°C were taken from a previous clinical study performed in Germany (39) . The samples were obtained from healthy smoking (n = 83) and nonsmoking (n = 25) volunteers. The smokers belonged to three groups, smoking cigarettes with 10 mg (n = 25), 4 mg (n = 33), and 1 mg (n = 25) tar as nicotine-free dry particulate matter (NFDPM), determined according to the ISO standard smoking regime.
Smokers were enrolled for 19 days and smoked a supplied brand of cigarette of similar blend, style, and tar and nicotine yields to their normal brand for the duration of the study. In addition, subjects kept a diary that recorded daily cigarette consumption, diet, exercise, and general health status. The nonsmoking group was enrolled for a total of 12 days (also recording diet, exercise, and health details).
The 24-h urine samples used for this study were taken on day 19 for the smoking groups and day 12 for the nonsmoking group.
The study protocol and informed consent forms were approved by the Ethics Committee (EC) of the Ärztekammer Hamburg, Germany and the clinical study was conducted in accordance with the World Medical Association Declaration of Helsinki and International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP) (40, 41) .
Urine sample preparation
Extraction of OH-PAH from human urine followed a previously published method (30) with some modifications. Urine was thawed at room temperature, agitated briefly, and centrifuged (2000 × g, 10 min, 10°C), in order to facilitate solidphase extraction (SPE) after the enzymatic hydrolysis. Centrifugation at this stage implicates the danger of losing analytes. In order to estimate the extent of losses of PAH metabolites, the pellet obtained after the centrifugation of 10 smoker urine samples was analyzed. Losses between 1 and 10% (mean 4%) were observed for the various PAH metabolites. Although losses up to 10% appear to be acceptable with regard to the overall accuracy of the method, it is advisable to skip the centrifugation step at this stage of the sample workup procedure. For enzymatic hydrolysis of conjugates, 10 mL urine was mixed with 20 mL acetate buffer (100 mM, pH 5.0). The pH of the mixture was adjusted to 5.0-5.05 (4 M HCl). After addition of 17 µL β-glucuronidase/arylsulfatase, the sample was incubated overnight (37°C, 16-20 h) with gentle agitation. The sample was transferred to a C18 cartridge (Bond Elut-C18, 500 mg, 3 mL, Varian, Darmstadt, Germany) that was conditioned with 7.5 mL methanol and 10 mL water. The cartridge was washed with 10 mL water and 10 mL methanol/water (1:4, v/v) and centrifuged (2000 × g, 10 min 10°C) to remove the excess solvent. Finally, the cartridge was thoroughly dried with a stream of nitrogen (1 bar, 0.5 h) and eluted with 10 mL n-hexane/methanol (100:0.7, v/v). Further purification of the primary extract was accomplished using a silica cartridge (Bond Elut-Si, 500 mg, 3 mL, Varian), conditioned with 10 mL n-hexane. Following elution of the analytes with 10 mL n-hexane/ethyl acetate (9:1, v/v), 20 µL DMSO was added to the extract, and the solvents, except the DMSO, were removed under reduced pressure at room temperature (Speed Vac concentrator, RC 10.22, Thermo, Dreieich, Germany). The residue was mixed with 200 µL methanol, and 10 µL of this solution was analyzed by HPLC-FD.
HPLC-FD
An Agilent HPLC system series 1100 (Agilent, Waldbronn, Germany) was used, consisting of a quaternary pump G1311A, a column oven G1316A, a degasser G1322A, and a liquid autosampler G1313A. For quantification, an Agilent programmable fluorescence detector (FD) 1046A was used. The OH-PAH were analyzed on a Synergi Polar-RP HPLC column (250 mm × 4.6 mm, 4-µm particle size, Phenomenex, Aschaffenburg, Germany) that was maintained at 40°C.
The two chromatographic solvents used were (A) potassium dihydrogen/disodium hydrogen phosphate buffer (10 mM, pH 5.5) and (B) methanol. A solvent gradient at a flow rate of 1 mL/min was applied as follows (% of solvent B given): 0-20 min: 56%, 20-45 min: 56-65%, 45-50 min: 65-90%, 50-55 min: 90-56%, and 55-65 min: 56%. The wavelengths for detection (excitation/emission) were programmed at intervals: 0-15 min: 1-OH-and 2-OH-Nap, 227/430 nm), 15-18 min: 2-OH-Flu (270/327 nm), 18-27 min: 2-OH-and 3-OH-Phe, 1-OH-and 9-OH-Phe (256/370 nm), 27-40 min: 1-OH-Pyr (240/387nm).
Calibration
For all analytes, external calibration was achieved by spiking synthetic urine (17) . Analysis of these samples (duplicates) yielded linear calibration curves. Because chromatographic co-elution appeared with respect to the isomers 2-OH-and 3-OH-Phe, and also 1-OH-and 9-OH-Phe, the sum of these pairs were determined for calibration using 2-OH-and 1-OH-Phe, respectively. In fact, 2-OH-and 3-OH-Phe as well as 1-OH-and 9-OH-Phe gave identical detector responses (data not shown). Calibration solutions were prepared in methanol at concentrations of 0.5, 5.0, and 500 µg/mL (1-OH-and 2-OH-Nap); 50.0 and 500 µg/mL (2-OH-Flu); and 5.0, 50.0, and 500 µg/mL 
Method validation
Method validation was performed according to FDA guidelines (42) . Specificity was measured using six different urine matrices, which were checked for interference with the analytes. As a criterion, the accuracy at a medium concentration level was tested in these six matrices for 1-OH-and 2-OH-Nap, 2-OH-Flu, 1-OH-and 2-OH-Phe, and 1-OH-Pyr.
Intraday precision was determined by evaluating three analyte concentration levels in authentic human urine samples, which were spiked with the required levels of the analytes. For intraday precision, each sample was analyzed five times. For interday precision, samples were analyzed once on six different days within two weeks.
Accuracies at low, medium, and high concentrations were determined with spiked synthetic (at the low level) or human urine samples. Each level was analyzed five times. Recovery rates were determined by comparing the analyte concentrations when the sample extract was spiked before the HPLC-FD measurements (reference, 100%), and when the urine was spiked before the sample clean-up procedure. Synthetic urine was used for the low, medium, and high levels.
Limits of detection (LOD) and quantification (LOQ) were estimated with the signal/peak-to-peak noise method using the integrated function of the HPLC software (Agilent ChemStation A.06.03). Signal/noise ratios of 3:1 were applied for estimating the LOD and LOQ. A second criterion for the LOQ level was that the deviation from the nominal concentration should not exceed 20%. A third criterion was a precision of < 20% at the LOQ level.
Short-term and long-term stability of the OH-PAHs were tested in human urine at 21°C (24 h) and -20°C (7 months). Samples were also tested for analyte losses at low and high concentrations following three freeze/thaw cycles. Carryover effects in the chromatographic system were tested by injecting urine extracts with high analyte concentrations five times, followed by sample solvent (methanol) injection. This was repeated three times. The solvent runs were checked for analyte peaks.
Matrix effects were determined by comparing the peak areas of the analytes (at low and high concentrations) in urine with those obtained in solvent.
Statistics
All statistical analyses were carried out with MINITAB ® v15.1, (MINITAB, State College, PA). Summary statistics were computed for each OH-PAH. A correlation matrix was produced to test relationships between the different OH-PAH and daily cigarette consumption. Power calculations were performed to determine the capacity of individual OH-PAH mark-ers to distinguish between discrete ISO tar yield groups. Analysis of covariance was carried out, with ISO tar yield as a factor, followed by post-ANOVA comparisons (Tukey's Honestly Significantly Different (HSD) test). Logarithmic transformation of the data improved the model fit (data not shown), and was used in all subsequent statistical analyses.
Results

Performance of the analytical method
Chromatograms of urine extracts from a nonsmoker and a smoker are shown in Figure 2 . The isomeric pairs of 1-OHPhe/9-OH-Phe and 2-OH-Phe/3-OH-Phe could not be separated and were therefore evaluated as a sum.
The method performance data are shown in Table I . Intraand interday precisions for all analytes were typically below 5%. Accuracy rates amounted to 94-106%. Recovery rates for the complete analytical procedure were > 80% for all OH-PAH, except for 1-OH-Pyr which had recoveries between 39 and 65%. Limits of detection (LOD) were approximately 0.3 ng/mL for 1-and 2-OH-Nap, 0.08 ng/mL for 2-OH-Flu, 0.01 ng/mL for the OH-Phe, and 0.003 ng/mL for 1-OH-Pyr.
Method specificity was determined as accuracy at a medium concentration in six different urine matrices. The values were found to range from 92 to 113%. No significant suppression or enhancement of the detector response was found in different urine matrices. The OH-PAH were found to be stable in urine for at least 24 h at 21°C, for at least seven months at -20°C, and during at least three freeze/thaw cycles (data not shown).
Urinary excretion of OH-PAH in smokers and nonsmokers
Mean, median, and ranges of the urinary levels of OH-PAH in nonsmokers and smokers [expressed as a concentration (ng/mL) and as a daily excretion rate (µg/24 h)] are shown in Table II . Smokers excreted significantly higher amounts of 1-and 2-OH-Nap, 2-OH-Flu, 2-/3-OH-Phe, 1-/9-OH-Phe, and 1-OH-Pyr than nonsmokers. In smokers, there was significant correlation between each of the OH-PAH and with the daily cigarette consumption (Table  III) . Smokers of cigarettes with 4 and 10 mg ISO tar excreted significantly higher amounts of all OH-PAH compared to nonsmokers, whereas smokers of 1 mg tar cigarettes only showed significant elevations compared to nonsmokers for daily excretion of 1-OH-Nap, 2-OH-Nap, and 2-OH-Flu (Figure 3 ). There was no statistically significant difference in OH-PAH excretion rates between smokers of 10 and 4 mg tar cigarettes. Smokers of 10 mg tar cigarettes excreted significantly higher amounts of all OH-PAH measured compared to smokers of 1 mg tar cigarettes, whereas smokers of 4 mg tar cigarettes excreted significantly higher amounts of 1-OH-Nap, 2-OH-Nap, 2-OH-Flu and 2-/3-OH-Phe compared to smokers of 1 mg tar cigarettes (Table II, Figure 3) .
A comparison was made between each individual smoker's elimination of OH-PAH and their mouth level exposure (MLE) to nicotine, as estimated by filter analysis (nicotine data were obtained from a previous study) (39) . The results from this comparison show significant correlations between each of the OH-PAH and daily nicotine mouth level exposure (Table III) .
Discussion
Scientists use biomarkers to track each phase of the dose-response continuum, from exposure through to effect. The pub- Sample number required to achieve 80% study power lished literature currently describes four basic biomarker groups in use today: biomarkers of exposure (which include markers of external exposure and of internal dose); biomarkers of biologically effective dose; biomarkers of effect (which include markers of health impairment and early disease precursors); and susceptibility biomarkers (which include intrinsic genetic or other characteristics or pre-existing diseases that result in an increase in internal dose, biologically effective dose, or target tissue response) (43) . Biomarkers are critical for evaluating the impacts of new strategies or products that aim to reduce exposure to tobacco smoke toxicants. It is probable that no single biomarker will satisfy such assessment needs, and so a panel of biomarkers must be used. The biomarkers should be assessed for their specificity, sensitivity, reproducibility, and ability to denote a dose-response relationship which is understood on a mechanistic basis (38) . In addition, the utility of new biomarkers must be established for different consumer populations (i.e., those varying in behavior, sex, age, genetics, and prior tobacco use).
With these selection criteria in mind, an HPLC-FD method was developed for the determination of 1-OH-Nap, 2-OH-Nap, 2-OH-Flu, 2-/3-OH-Phe, 1-/9-OH-Phe, and 1-OH-Pyr in the urine of non-occupationally exposed persons. The described method is a modification of a previously published method (30) , and comprised the analytical column used for separation of the analytes and the excitation/emission wavelength used for 1-and 2-Nap. The column described by Chetiyanukronkul et al. (30) (RP-Amide C16) was found to be unstable after 8 days of use and was, therefore, replaced with a "polar RP" column with similar properties but somewhat less separation power. This resulted in a loss of separation of 2-and 3-OH-Phe, as well as 1-OH-Pyr and 1-OH-Pyr-d 9 . The modification was necessary, however, as the method was designed to be applied to larger sample series. The exitation/emission wavelengths for the naphthols was also changed in order to avoid interferences. Furthermore, the detector gain was adjusted to a range which allowed the quantification of the OH-PAH in the majority of the urine samples analyzed. This led to an impairment of the LOQ for 2-OH-Nap (17-fold) and 2-OH-Flu (15-fold), which was deemed to be acceptable for our sample series. The method performance met the FDA accepted criteria for bioanalytical methods (42) . In particular, LODs were sufficiently low for measuring OH-PAH in non-occupationally exposed nonsmokers. The recovery rates were > 80% for all analytes, except for 1-OH-Pyr. The rather low recovery rate for 1-OH-Pyr (39-65%) was presumably due to its incomplete retention on the silica cartridge. In the current method, elution from the C 18 cartridge was only possible using a small percentage of methanol (n-hexane/methanol, 100:0.7, v/v), instead of pure n-hexane, as described by Chetiyanukronkul et al. (30) . Because the eluate was applied directly to the silica cartridge, the methanol content may have resulted in some losses of the most apolar analyte (1-OH-Pyr). The advantages of the described method include the high sensitivity of the fluorescence detection for PAH metabolites without derivatization, and the general availability of the required instrumentation (HPLC-FD) across many laboratories. The LOQ of the current method is similar to LC-MS-MS (17) and GC-HRMS (25) multi-OH-PAH methods reported by others. The disadvantages include the labor-intensive sample work-up procedure, the limited separation power of HPLC (too low for the two OH-Phe isomer pairs), the limited responsiveness of the fluorescence detector, and the lack of applicability of authentic internal standards.
The method was capable of detecting the selected OH-PAH in all urine samples analyzed. Significant amounts of OH-PAH were detected in nonsmoker urine samples, with confounders such as diet contributing to the observed levels (44) . Significantly higher urinary daily excretion rates of 1-OH-Pyr, 1-OHNap, 2-OH-Nap, 2-OH-Flu, 2-/3-OH-Phe, and 1-/9-OH-Phe were observed in smokers compared to nonsmokers (Table II) . For instance, an approximately twofold higher level of urinary 1-OH-Pyr was observed in smokers compared to nonsmokers. The absolute levels of 1-OH-Pyr in urine were comparable to those found in the published literature (21) .
In general, the results from this study are in agreement with other published data (17, 23) , with a number of exceptions. One study conducted by Benowitz and colleagues (22) , which comprised smokers who switched from their usual brand (average of 14.4 mg ISO tar) to lower ISO tar yielding cigarettes for one week (approximately 50% tar reduction), then returned to their usual brand, observed levels of 1-/2-OH-Nap of 26.1, 24.0, and 25.7 ng/mg creatinine. This level is in good agreement with the average 1-/2-OH-Nap concentration of 21.5 ng/mL for smokers observed in this study, when an average creatinine concentration of 1 mg/mL is assumed. However, Benowitz et al. (22) observed no significant difference in 1-/2-OH-Nap between the usual brand (14.4 mg) and lower ISO tar cigarette smokers, in contrast to the differences shown in this study among the 10, 4, and 1 mg ISO tar smokers. The authors suggest that this lack of distinction between groups is attributable to modifications in smoking behavior ("compensation") on the part of the switching group. The low participant number in the Benowitz study (n = 16 healthy smokers) (22) may have also been a factor, given the high level of interindividual variation observed. Preuss et al. (23) reported median levels of 5.0 and 20.6 ng/mL for 1-OH-Nap in nonsmokers and smokers from the general population, respectively. These levels exceed the median 1-OH-Nap levels observed in our study (1.32 versus 7.03 ng/mL), although the ratio (smokers/nonsmokers) is similar in both studies. The authors also reported median levels of 3.6 and 19.5 ng/mL for 2-OH-Nap in urine of non-occupationally exposed nonsmokers and smokers, respectively, which is again higher than we observed (2.4 versus 14.3 ng/mL).
A study conducted in a U.S. population during 1999-2000 (25) , comprised of nonsmoking subjects ≥ 20 years of age, reported median levels of urinary 2-OH-Fl and 2-/3-OH-Phe of 0.46 and 0.24 ng/mL, which is similar to the median levels of 0.45 and 0.26 ng/mL found in this study.
Although comparisons of the levels of individual urinary OH-Phe are somewhat limited, the reported levels for nonsmokers and smokers in the published literature are in the same range as observed in this study. For the sum of hydroxyphenanthrenes, comprising 1-, 2-, 3-, and 4-OH-Phe, Jacob et al. (17) reported means of 0.91 and 0.29 ng/mg creatinine in the urine of smokers and nonsmokers, respectively. These were moderately different from the average urinary concentrations observed in this study for hydroxyphenanthrenes (including 1-, 2-, 3-, and 9-OH-Phe) of 0.82 and 0.54 ng/mL for smokers and nonsmokers, respectively. It should be noted that 4-OH-Phe was not quantifiable in urine with our method, due to a combination of naturally low concentrations and matrix interference.
The association between urinary OH-PAH and various measures of smoking-related exposure was also investigated in this study. For example, urinary excretion of OH-PAH significantly correlated with the number of cigarettes smoked per day (r = 0.34-0.63, p < 0.001, Table III), which corroborates the findings from earlier studies (44) (45) (46) . A reduced exposure to PAH, as measured by urinary 1-OH-Pyr, has also been observed following the switch to cigarettes with reduced levels of PAH, with results reported from both spot urine (pmol/mg creatinine) (47, 48) and 24 h urine (µg/24 h) (45) . These generally agree with the reduced daily excretion rates of OH-PAH observed in this study using lower ISO tar yield cigarettes (Figure 3) . The amounts of OH-PAH in urine were significantly lower when smoking 1 mg tar cigarettes compared to smoking 4 or 10 mg tar cigarettes. There was no significant difference in terms of OH-PAH intake between smoking 4 and 10 mg tar cigarettes.
Because the daily cigarette consumption was not significantly different between the three tar groups, it can be concluded that in this study population smoking 1 mg tar cigarettes led on average to a reduced PAH exposure of 40-50% compared to smoking 4 or 10 mg tar cigarettes, although the reduction is lower than the reduction in nominal yields (75 or 90%). This observation is consistent with different smoking behavior when smoking lower yield cigarettes (47) .
The power of each selected OH-PAH biomarker to distinguish individual ISO tar yield smoking groups from each other, and the sample number required to satisfy a minimum 80% discriminatory study power, are shown in Table II . The values give an indication of the biomarker's capacity to establish a dose-response element for the OH-PAH biomarkers as a group (38) . They also indicate whether newly developed technologies designed to reduce PAH exposure from cigarette smoke will be suitably assessed using these biomarker methods. The results show that larger sample numbers are required to suitably distinguish 10 from 4 mg ISO tar smokers, compared to 4 versus 1 mg and 1 mg versus nonsmokers. In general, metabolites of phenanthrene and pyrene appear to be more suitable for distinguishing between smokers of 10 mg tar cigarettes and smokers of 4 mg tar cigarettes, compared to the metabolites of naphthalene. The individual power values also indicate that in future clinical studies, a careful assessment of study sample numbers should be carried out to ensure that sufficient study power can be achieved to differentiate smokers of products falling within a particular ISO tar yield range.
A final comparison was made between each individual smoker's OH-PAH and their mouth level exposure (MLE) to nicotine, as estimated by filter analysis (nicotine data were previously obtained from a clinical study completed in Germany, which is described in detail in the Methods section) ( Table III) . The filter analysis methodology described is indirect, and has been shown previously to be a reliable indicator of the amount of nicotine exiting the cigarette filter (49, 50) . The results show significant correlations between each of the OH-PAH and MLE nicotine, and indicate the alignment of the biomarker data with smoking behavior. Furthermore, the data support the use of these biomarkers in estimating exposure to PAH from cigarette smoke.
In conclusion, the described analytical method for the determination of the phenolic metabolites of naphthalene, fluorene, phenanthrene and pyrene is suitable for assessing a profile of environmental and smoking-related OH-PAH in human urine. Results of the application show that this method can be used to assess PAH exposure associated with the use of tobacco products, including future potential reduced exposure products.
